Peregrine Pharmaceuticals Inc. 10.5% Conv. Pfd. Series E (PPHMP) News Nov 20, 2014, 3:10 p.m.
MarketWatch News on PPHMP
No News currently available for PPHMP
Other News on PPHMP
No News currently available for PPHMP
Press Releases on PPHMP
Phase II Clinical Data Presented at SITC Annual Meeting Support Immunotherapeutic Mechanism of Action of Peregrine Pharmaceuticals' Bavituximab in Liver Cancer 7:32 a.m. Nov. 10, 2014 - Marketwired
Data to Be Presented at the SITC Annual Meeting Support Synergy of PS-Targeting and Anti-CTLA-4 Immunotherapies to Enhance Anti-Tumor Treatments in Melanoma 7:45 a.m. Nov. 7, 2014 - Marketwired
Promising Data Presented at the Chicago Multidisciplinary Symposium on Thoracic Oncology From an Investigator-Sponsored Trial of Peregrine Pharmaceuticals' Bavituximab in Combination With Pemetrexed and Carboplatin in Front-Line Non-Small Cell Lung Cancer 8:43 a.m. Oct. 30, 2014 - Marketwired
Data to Be Published in the Journal of Immunology Research Support Phosphatidylserine (PS) as a Potential Target in Ebola Infection 7:05 a.m. Oct. 15, 2014 - Marketwired
Data to Be Presented at CRI Immunotherapy Conference Show PS-Targeting Antibodies Enhance the Anti-Tumor Activity of Immune Checkpoint Inhibitors by Decreasing Levels of Myeloid Derived Suppressor Cells (MDSC) in the Tumor Microenvironment 7:03 a.m. Oct. 6, 2014 - Marketwire
Peregrine Pharmaceuticals Reports First Quarter Fiscal Year 2015 Financial Results and Recent Developments 3:01 p.m. Sept. 9, 2014 - Marketwire
Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock 3:00 p.m. Sept. 8, 2014 - Marketwire
Peregrine Pharmaceuticals to Report First Quarter Fiscal Year 2015 Financial Results After Market Close on September 9, 2014 3:01 p.m. Sept. 2, 2014 - Marketwire
Preclinical Data Presented at Annual Immunotherapies and Vaccine Summit Show That the Combination of Peregrine Pharmaceuticals' PS-Targeting Antibodies and Anti-PD-1 Antibodies Significantly Reduce Breast Cancer Progression 7:03 a.m. Aug. 11, 2014 - Marketwire
Peregrine Pharmaceuticals Reports Fourth Quarter and Year-End Fiscal Year 2014 Financial Results and Recent Developments 3:01 p.m. July 14, 2014 - Marketwire
Peregrine Pharmaceuticals to Report Fourth Quarter and Year-End Fiscal 2014 Financial Results After Market on July 14, 2014 3:00 p.m. July 7, 2014 - Marketwire
Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock 3:00 p.m. June 10, 2014 - Marketwire
Peregrine Pharmaceuticals Announces Initiation of an Investigator-Sponsored Trial Combining Its Immunotherapy Bavituximab and Ipilimumab (Yervoy(R)) in Advanced Melanoma 6:31 a.m. April 23, 2014 - Marketwire
Data Presented at AACR Support Potential of Peregrine's PS-Targeting Immunotherapy Bavituximab to Enhance Anti-Tumor and Immune-Stimulating Effects of Anti-CTLA-4 and Anti-PD-1 Treatments in Models of Melanoma and Colon Cancer 10:01 a.m. April 9, 2014 - Marketwire
Data Presented at AACR Support Potential of Combining Peregrine's PS-Targeting Immunotherapy Agent Bavituximab With Irradiation in Lung Cancer 7:04 a.m. April 7, 2014 - Marketwire
Peregrine Pharmaceuticals Announces Three Abstracts Accepted for Presentation at AACR 2014 Annual Meeting 3:01 p.m. April 1, 2014 - Marketwire
Presentation at Annual Society of Surgical Oncology Meeting Updates Progress in Investigator-Sponsored Phase i/ii Trial of Peregrine's Bavituximab in Combination With Sorafenib in Liver Cancer 7:02 a.m. March 14, 2014 - Marketwire
Preclinical Data Presentations at Keystone Symposia Highlight Broad Immunotherapy Potential of Peregrine Pharmaceuticals' PS-Targeting Antibodies 7:02 a.m. March 13, 2014 - Marketwire
Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock 3:11 p.m. March 11, 2014 - Marketwire
Data Presentations at Keystone Symposium Support Potential of Peregrine Pharmaceuticals' PS-Targeting Antibodies to Overcome Immune Suppression and Enhance Anti-Tumor Activity of Anti-CTLA-4 and PD-1 Antibodies 7:04 a.m. March 11, 2014 - Marketwire
MarketWatch News on PPHMP
No News currently available for PPHMP
Other News on PPHMP
No News currently available for PPHMP
Press Releases on PPHMP
Phase II Clinical Data Presented at SITC Annual Meeting Support Immunotherapeutic Mechanism of Action of Peregrine Pharmaceuticals' Bavituximab in Liver Cancer 7:32 a.m. Nov. 10, 2014 - Marketwired
Data to Be Presented at the SITC Annual Meeting Support Synergy of PS-Targeting and Anti-CTLA-4 Immunotherapies to Enhance Anti-Tumor Treatments in Melanoma 7:45 a.m. Nov. 7, 2014 - Marketwired
Promising Data Presented at the Chicago Multidisciplinary Symposium on Thoracic Oncology From an Investigator-Sponsored Trial of Peregrine Pharmaceuticals' Bavituximab in Combination With Pemetrexed and Carboplatin in Front-Line Non-Small Cell Lung Cancer 8:43 a.m. Oct. 30, 2014 - Marketwired
Data to Be Published in the Journal of Immunology Research Support Phosphatidylserine (PS) as a Potential Target in Ebola Infection 7:05 a.m. Oct. 15, 2014 - Marketwired
Data to Be Presented at CRI Immunotherapy Conference Show PS-Targeting Antibodies Enhance the Anti-Tumor Activity of Immune Checkpoint Inhibitors by Decreasing Levels of Myeloid Derived Suppressor Cells (MDSC) in the Tumor Microenvironment 7:03 a.m. Oct. 6, 2014 - Marketwire
Peregrine Pharmaceuticals Reports First Quarter Fiscal Year 2015 Financial Results and Recent Developments 3:01 p.m. Sept. 9, 2014 - Marketwire
Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock 3:00 p.m. Sept. 8, 2014 - Marketwire
Peregrine Pharmaceuticals to Report First Quarter Fiscal Year 2015 Financial Results After Market Close on September 9, 2014 3:01 p.m. Sept. 2, 2014 - Marketwire
Preclinical Data Presented at Annual Immunotherapies and Vaccine Summit Show That the Combination of Peregrine Pharmaceuticals' PS-Targeting Antibodies and Anti-PD-1 Antibodies Significantly Reduce Breast Cancer Progression 7:03 a.m. Aug. 11, 2014 - Marketwire
Peregrine Pharmaceuticals Reports Fourth Quarter and Year-End Fiscal Year 2014 Financial Results and Recent Developments 3:01 p.m. July 14, 2014 - Marketwire
Peregrine Pharmaceuticals to Report Fourth Quarter and Year-End Fiscal 2014 Financial Results After Market on July 14, 2014 3:00 p.m. July 7, 2014 - Marketwire
Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock 3:00 p.m. June 10, 2014 - Marketwire
Peregrine Pharmaceuticals Announces Initiation of an Investigator-Sponsored Trial Combining Its Immunotherapy Bavituximab and Ipilimumab (Yervoy(R)) in Advanced Melanoma 6:31 a.m. April 23, 2014 - Marketwire
Data Presented at AACR Support Potential of Peregrine's PS-Targeting Immunotherapy Bavituximab to Enhance Anti-Tumor and Immune-Stimulating Effects of Anti-CTLA-4 and Anti-PD-1 Treatments in Models of Melanoma and Colon Cancer 10:01 a.m. April 9, 2014 - Marketwire
Data Presented at AACR Support Potential of Combining Peregrine's PS-Targeting Immunotherapy Agent Bavituximab With Irradiation in Lung Cancer 7:04 a.m. April 7, 2014 - Marketwire
Peregrine Pharmaceuticals Announces Three Abstracts Accepted for Presentation at AACR 2014 Annual Meeting 3:01 p.m. April 1, 2014 - Marketwire
Presentation at Annual Society of Surgical Oncology Meeting Updates Progress in Investigator-Sponsored Phase i/ii Trial of Peregrine's Bavituximab in Combination With Sorafenib in Liver Cancer 7:02 a.m. March 14, 2014 - Marketwire
Preclinical Data Presentations at Keystone Symposia Highlight Broad Immunotherapy Potential of Peregrine Pharmaceuticals' PS-Targeting Antibodies 7:02 a.m. March 13, 2014 - Marketwire
Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock 3:11 p.m. March 11, 2014 - Marketwire
Data Presentations at Keystone Symposium Support Potential of Peregrine Pharmaceuticals' PS-Targeting Antibodies to Overcome Immune Suppression and Enhance Anti-Tumor Activity of Anti-CTLA-4 and PD-1 Antibodies 7:04 a.m. March 11, 2014 - Marketwire
